A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia
暂无分享，去创建一个
H. Döhner | A. Califano | M. Heuser | O. Frankfurt | M. Alvarez | M. Showel | Yao Shen | G. Roboz | B. Bhatnagar | E. Raffoux | J. Shah | K. Sweet | Y. Landesman | S. Shacham | S. Strickland | M. Savona | P. Montesinos | C. Röllig | V. Kota | W. Donnellan | M. Crochiere | M. Kauffman | Hongtao Liu | T. Unger | S. Vives | Shijie Tang | A. Joshi